GCC Viscosupplementation Market Research Report By Type (Stabilized Hyaluronic Acid, Standard hyaluronic) and By Procedure (Three-Injection Procedure)- Forecast to 2035

GCC Viscosupplementation Market Overview

As per MRFR analysis, the GCC Viscosupplementation Market Size was estimated at 71.01 (USD Million) in 2023.The GCC Viscosupplementation Market Industry is expected to grow from 80(USD Million) in 2024 to 120 (USD Million) by 2035. The GCC Viscosupplementation Market CAGR (growth rate) is expected to be around 3.755% during the forecast period (2025 - 2035)

Key GCC Viscosupplementation Market Trends Highlighted

Driven by a rise in orthopaedic diseases and a rising knowledge of osteoarthritis treatment choices among the populace, the GCC Viscosupplementation Market is seeing many notable developments. The growing prevalence of knee osteoarthritis, especially in nations like Saudi Arabia and the UAE, underlines the need for efficient treatment options. Gaining popularity as a non-surgical way to reduce discomfort and increase mobility is viscosupplementation, which injects hyaluronic acid into the joints. Healthcare projects in the GCC that aim to improve patient care and access to innovative therapies help to support this even more.

Driven by technological developments in medical devices and medicines, the GCC industry is growing with possibilities. Emerging are creative product advancements improving the efficacy and safety of viscosupplementation therapies. In addition, further cooperation between local distributors and foreign viscosupplement makers offers a calculated path for market expansion. The move toward less invasive surgeries fits patient tastes and is motivating more doctors to choose viscosupplementation as a feasible therapy choice. Recent trends point to increasing interest in personalized medicine, where treatments are customized to particular patient requirements, notably in the management of joint problems.

Aiming to provide thorough services that support developing treatments like viscosupplementation, the GCC governments are investing in healthcare infrastructure. This investment helps to create a climate favourable to market expansion, hence enabling broader access to new therapies. These developments, taken together, imply a dynamic evolution of the GCC Viscosupplementation Market as it adapts to the demands and tastes of the people of the area.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

GCC Viscosupplementation Market Drivers

Aging Population in GCC Region

The GCC Viscosupplementation Market Industry is significantly driven by the aging population in the Gulf Cooperation Council countries. According to government statistics from National Center for Statistics and Information, as of recent reports, there has been a notable increase in the percentage of individuals aged 60 and above, projected to reach 20% of the total population by 2030. This demographic shift correlates with an increase in osteoarthritis and joint disorders, which often require viscosupplementation treatments.

The increase in demand for non-surgical therapies for osteoarthritis, owing to less invasive nature and quicker recovery times, is being noted in established healthcare systems across the region. Prominent organizations such as the Saudi Ministry of Health are actively promoting preventative measures and work to improve healthcare access and awareness, thus increasing the attractiveness of viscosupplementation therapies in treating joint pain and improving mobility in older adults.The growing trend towards preventive healthcare is likely to bolster the GCC Viscosupplementation Market.

Rising Prevalence of Osteoarthritis

The GCC Viscosupplementation Market Industry is boosted by the rising prevalence of osteoarthritis, which is becoming a major concern in the region. According to the World Health Organization, osteoarthritis affects over 27 million individuals in the Middle East. The GCC nations, known for their increasing sedentary lifestyles and obesity rates, are experiencing a surge in the diagnosis of this degenerative joint disease. The Ministry of Health in the United Arab Emirates has documented a 15% rise in reported osteoarthritis cases over the past five years, highlighting the growing need for effective treatment options like viscosupplementation.This presents a significant opportunity for healthcare providers and manufacturers of viscosupplementation products to cater to this increasing patient population seeking relief from joint pain.

Advancements in Medical Technology

Advancements in medical technology play a crucial role in the growth of the GCC Viscosupplementation Market Industry. Innovations such as improved hyaluronic acid formulations and delivery mechanisms have made viscosupplementation treatments more effective and appealing. Reports indicate that the introduction of biologically enhanced viscosupplements has demonstrated better patient outcomes and longer-lasting relief. Furthermore, regional healthcare centers are increasingly adopting state-of-the-art equipment for administering viscosupplementation, aligning with initiatives by healthcare authorities, such as the Qatar Ministry of Public Health, which is investing in the latest technologies to enhance patient care experience.The investment in training for medical professionals on these new technologies further supports the burgeoning market, as healthcare providers can offer more effective and efficient treatments.

GCC Viscosupplementation Market Segment Insights

Viscosupplementation Market Type Insights

The GCC Viscosupplementation Market is an evolving segment within the healthcare sector, primarily focused on alleviating joint pain, particularly in osteoarthritis patients. This market has gained considerable traction in the GCC region, propelled by increasing awareness of joint health, rising healthcare expenditures, and an aging population. Among the types of viscosupplementation offerings, Stabilized Hyaluronic Acid has emerged as a prominent player, known for its enhanced efficacy and prolonged therapeutic effects. Such advantages make it a preferred option for healthcare providers and patients, contributing to its significant role in the market.In contrast, Standard Hyaluronic Acid remains a staple due to its established profile and affordability, catering to a broader patient demographic. 

The growth of both types has been encouraged by advancements in technology that improve product formulations and innovations in medical practices, creating a landscape ripe for expansion. Furthermore, the GCC region’s commitment to improving healthcare infrastructure and services is likely to further stimulate the market, along with an increase in collaborative efforts among healthcare stakeholders.The evolving regulatory framework within the GCC is also adapting to accommodate these innovative treatments, fostering a conducive environment for growth. The rise in chronic diseases, particularly among the middle-aged and elderly sectors within the GCC population, has underscored the necessity for effective pain management solutions, reaffirming the relevance of viscosupplementation in addressing these concerns. 

Additionally, increasing interest in minimally invasive procedures is enhancing the appeal of these treatments, leading to a positive outlook for the GCC Viscosupplementation Market overall.Overall, as both Stabilized and Standard Hyaluronic Acid continue to evolve and cater to specific patient needs, they are poised to play a crucial role in shaping the future of joint treatment strategies in the GCC region.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Viscosupplementation Market Procedure Insights

The Procedure segment of the GCC Viscosupplementation Market encompasses various techniques employed for administering viscosupplementation treatments, which are primarily aimed at alleviating osteoarthritis symptoms. A notable approach within this segment is the Three-Injection Procedure, which is increasingly favored due to its comprehensive treatment protocol. This method involves multiple injections over a specified period, allowing for sustained relief from joint pain and improved mobility. The significance of the Three-Injection Procedure lies in its ability to gradually enhance the distribution of hyaluronic acid in the joint, promoting better outcomes for patients experiencing degenerative joint diseases.

The GCC region has witnessed a growing demand for such innovative treatment methodologies as awareness regarding joint health improves, coupled with an increase in the aging population. Medical practitioners emphasize the importance of procedural integrity and patient compliance in achieving optimal therapeutic effects. Furthermore, trends indicate that advancements in technology and product formulations will likely lead to enhanced efficacy and patient satisfaction within the Three-Injection segment, contributing positively to the overall GCC Viscosupplementation Market dynamics.

GCC Viscosupplementation Market Key Players and Competitive Insights

The GCC Viscosupplementation Market has been gaining traction due to the growing incidence of osteoarthritis and the increasing aging population in the region. This has led to a heightened demand for joint pain relief treatments, among which viscosupplementation is recognized for its efficacy in alleviating symptoms by restoring lubricant properties in synovial fluid. With several companies competing to establish their foothold in this market, the competitive landscape is influenced by factors such as product innovations, regulatory approvals, distribution agreements, and pricing strategies. Companies are emphasizing research and development to introduce new products that offer improved efficacy and safety profiles. 

As the awareness and acceptance of viscosupplementation therapies increase in healthcare practices across the GCC, the competitive dynamics continue to evolve, shaped by both local and international players.Orthogen has made significant strides in the GCC Viscosupplementation Market with its advanced product offerings. The company's commitment to research and development has enabled it to introduce a range of effective viscosupplementation solutions tailored to meet the needs of patients suffering from joint-related issues. Its strong presence is attributed to the strategic alliances it has formed with local distributors and healthcare providers, allowing for efficient penetration of the market. Orthogen's strengths lie in its ability to respond quickly to market demands and regulatory changes while maintaining a strict focus on product quality and safety. 

The company's innovative approaches and responsiveness have positioned it favorably amidst growing competition in the region.Merz Pharmaceuticals is another key player in the GCC Viscosupplementation Market, renowned for its broad portfolio of healthcare products. The company offers advanced viscosupplementation solutions that target joint pain, significantly improving patients' quality of life. Merz Pharmaceuticals has established a solid market presence in the GCC through effective partnerships and collaborations, ensuring its products are widely accessible across various healthcare settings. One of the company’s key strengths is its commitment to ongoing research and development, which enables it to continually innovate and enhance its product offerings. 

Furthermore, Merz Pharmaceuticals has been involved in strategic mergers and acquisitions, enhancing its capabilities and market reach within the GCC. This strategic positioning paired with a robust network of healthcare professionals contributes to the company’s competitive advantage, allowing it to thrive in a challenging market landscape focused on joint health solutions.

Key Companies in the GCC Viscosupplementation Market Include

• Orthogen


• Merz Pharmaceuticals


• Hyaluronic Acid Injectable


• Fidia Farmaceutici


• DePuy Synthes


• Bioventus


• Stryker


• Mediwink


• Revive Therapeutics


• Allergan


• Innocoll


• NexMed


• Sanofi


• Zimmer Biomet

GCC Viscosupplementation Market Industry Developments

Recent developments in the GCC Viscosupplementation Market indicate a growing demand for hyaluronic acid injectable treatments, driven by an increase in osteoarthritis cases and aging populations. Notably, in November 2022, Orthogen launched a new line of viscosupplementation injections aimed at improving patient outcomes in joint pain management, reflecting a broader trend toward innovative solutions among key players like Merz Pharmaceuticals and Stryker. The market has also seen advancements in product formulations and delivery systems, enhancing the efficacy and safety of treatments.

Current affairs highlight a robust growth trajectory, with Fidia Farmaceutici reporting a significant increase in their market share in the region following the introduction of a novel viscoelastic product in early 2023. In terms of mergers and acquisitions, Zimmer Biomet announced the acquisition of NexMed's hyaluronic acid product line in May 2023, a move aimed at strengthening their portfolio in the viscosupplementation sector. The increased competition among leading companies, including Bioventus and Allergan, has contributed to descending prices while improving product accessibility in the GCC, thereby benefiting a larger patient demographic.

GCC Viscosupplementation Market Segmentation Insights

• Viscosupplementation Market Type Outlook
  
  
  
  • Stabilized Hyaluronic Acid
  
  
  • Standard hyaluronic
  
  
  
  


• Viscosupplementation Market Procedure Outlook
  
  
  
  • Three-Injection Procedure
  
  
  
  

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	71.01(USD Million)
MARKET SIZE 2024	80.0(USD Million)
MARKET SIZE 2035	120.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	3.755% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Orthogen, Merz Pharmaceuticals, Hyaluronic Acid Injectable, Fidia Farmaceutici, DePuy Synthes, Bioventus, Stryker, Mediwink, Revive Therapeutics, Allergan, Innocoll, NexMed, Sanofi, Zimmer Biomet
SEGMENTS COVERED	Type, Procedure
KEY MARKET OPPORTUNITIES	Rising aging population demand, Increasing prevalence of osteoarthritis, Growth of minimally invasive procedures, Expansion of healthcare infrastructure, Surge in sports-related injuries
KEY MARKET DYNAMICS	Rising prevalence of arthritis, Increasing geriatric population, Growing demand for minimally invasive procedures, Expanding distribution channels, Advancements in product formulations
COUNTRIES COVERED	GCC